Drew Provan

12.6k total citations · 2 hit papers
107 papers, 6.2k citations indexed

About

Drew Provan is a scholar working on Hematology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Drew Provan has authored 107 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Hematology, 29 papers in Pathology and Forensic Medicine and 27 papers in Genetics. Recurrent topics in Drew Provan's work include Platelet Disorders and Treatments (72 papers), Blood groups and transfusion (51 papers) and Autoimmune Bullous Skin Diseases (26 papers). Drew Provan is often cited by papers focused on Platelet Disorders and Treatments (72 papers), Blood groups and transfusion (51 papers) and Autoimmune Bullous Skin Diseases (26 papers). Drew Provan collaborates with scholars based in United Kingdom, United States and Italy. Drew Provan's co-authors include Roberto Stasi, Adrian C. Newland, James B. Bussel, Nichola Cooper, Bertrand Godeau, Douglas B. Cines, Marc Michel, Sergio Amadori, Donald M. Arnold and Francesco Rodeghiero and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Drew Provan

101 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

2008 1.9k citations Francesco Rodeghiero, Roberto Stasi et al. Blood profile →
Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura

2007 565 citations James B. Bussel, Gregory Cheng et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Drew Provan United Kingdom	35	5.1k	1.4k	1.3k	951	813	107	6.2k
Nichola Cooper United Kingdom	33	5.9k 1.2×	1.8k 1.2×	1.4k 1.1×	896 0.9×	1.3k 1.6×	141	7.2k
Prashant Kapoor United States	40	4.0k 0.8×	502 0.4×	1.3k 1.0×	191 0.2×	504 0.6×	327	6.2k
Monique C. Minnema Netherlands	39	2.9k 0.6×	1.2k 0.8×	1.6k 1.2×	231 0.2×	1.0k 1.2×	229	5.6k
Jean‐Paul Fermand France	34	1.8k 0.4×	445 0.3×	890 0.7×	303 0.3×	792 1.0×	105	4.4k
Abdulgabar Salama Germany	32	2.4k 0.5×	330 0.2×	770 0.6×	341 0.4×	1.2k 1.4×	141	4.4k
Jan‐Stephan Sanders Netherlands	34	1.8k 0.3×	264 0.2×	802 0.6×	1.2k 1.3×	875 1.1×	168	4.2k
Philippe Casassus France	30	3.3k 0.6×	604 0.4×	773 0.6×	1.7k 1.7×	674 0.8×	80	6.1k
JG Kelton Canada	32	4.4k 0.9×	509 0.4×	461 0.3×	668 0.7×	694 0.9×	67	6.2k
Georges Fillet Belgium	37	2.0k 0.4×	2.1k 1.5×	1.4k 1.1×	865 0.9×	481 0.6×	151	5.3k
Jamie Cavenagh United Kingdom	40	4.6k 0.9×	300 0.2×	1.1k 0.9×	237 0.2×	1.8k 2.2×	141	6.7k

Countries citing papers authored by Drew Provan

Since Specialization

Citations

This map shows the geographic impact of Drew Provan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Drew Provan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Drew Provan more than expected).

Fields of papers citing papers by Drew Provan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Drew Provan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Drew Provan. The network helps show where Drew Provan may publish in the future.

Co-authorship network of co-authors of Drew Provan

This figure shows the co-authorship network connecting the top 25 collaborators of Drew Provan. A scholar is included among the top collaborators of Drew Provan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Drew Provan. Drew Provan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Provan, Drew, et al.. (2024). Tapering and Sustained Remission of Thrombopoietin Receptor Agonists (TPO-RAs): Is it Time for Paediatric ITP?. Advances in Therapy. 41(10). 3771–3777. 1 indexed citations

Provan, Drew, Jecko Thachil, & María Román. (2024). Addressing thrombosis concerns in immune thrombocytopenia: the role of fostamatinib in immune thrombocytopenia management. Expert Review of Hematology. 17(1-3). 55–66. 3 indexed citations

Li, Qian, Geneviève Marcoux, Johan Rebetz, et al.. (2024). Autoimmune effector mechanisms associated with a defective immunosuppressive axis in immune thrombocytopenia (ITP). Autoimmunity Reviews. 23(12). 103677–103677. 9 indexed citations

González‐López, Tomás José, Adrian C. Newland, & Drew Provan. (2023). Current Concepts in the Diagnosis and Management of Adult Primary Immune Thrombocytopenia: Our Personal View. Medicina. 59(4). 815–815. 5 indexed citations

González‐López, Tomás José, Drew Provan, Abelardo Bárez, et al.. (2023). Primary and secondary immune thrombocytopenia (ITP): Time for a rethink. Blood Reviews. 61. 101112–101112. 18 indexed citations

Yazdanbakhsh, Karina, Drew Provan, & John W. Semple. (2023). The role of T cells and myeloid‐derived suppressor cells in refractory immune thrombocytopenia. British Journal of Haematology. 203(1). 54–61. 12 indexed citations

González‐López, Tomás José & Drew Provan. (2022). Proposal for a New Protocol for the Management of Immune Thrombocytopenia (ITP). Advances in Therapy. 39(6). 2287–2291. 6 indexed citations

Grant, Laura, Nichola Cooper, Donald M. Arnold, et al.. (2021). Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia. Advances in Therapy. 38(12). 5791–5808. 6 indexed citations

Cooper, Nichola, Adam Cuker, Nicola Bonner, et al.. (2021). Qualitative study to support the content validity of the immune thrombocytopenia (ITP) Life Quality Index (ILQI). British Journal of Haematology. 194(4). 759–766. 9 indexed citations

10.

Cooper, Nichola, Caroline Kruse, Shirley Watson, et al.. (2020). Immune thrombocytopenia (ITP) World Impact Survey (I‐WISh): Impact of ITP on health‐related quality of life. American Journal of Hematology. 96(2). 199–207. 63 indexed citations

11.

Bennett, Dimitri, et al.. (2016). Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta‐analysis. European Journal Of Haematology. 97(4). 321–330. 55 indexed citations

12.

Hallam, Simon, Drew Provan, & Adrian C. Newland. (2013). Immune thrombocytopenia – what are the new treatment options?. Expert Opinion on Biological Therapy. 13(8). 1173–1185. 14 indexed citations

13.

Rodeghiero, Francesco, Roberto Stasi, Terry Gernsheimer, et al.. (2008). Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 113(11). 2386–2393. 1853 indexed citations breakdown →

14.

Stasi, Roberto & Drew Provan. (2008). Helicobacter pylori and Chronic ITP. Hematology. 2008(1). 206–211. 52 indexed citations

15.

Psaila, Bethan, Drew Provan, John M. Hamilton, et al.. (2007). The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. British Journal of Haematology. 138(2). 245–248. 124 indexed citations

16.

Bussel, James B., et al.. (2007). Safety of Eltrombopag, an Oral Non-Peptide Platelet Growth Factor, in the Treatment of Thrombocytopenia: Results of Four Randomized, Placebo-Controlled Studies. Blood. 110(11). 1299–1299. 8 indexed citations

17.

Bussel, James B., Gregory Cheng, Mansoor N. Saleh, et al.. (2007). Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura. New England Journal of Medicine. 357(22). 2237–2247. 565 indexed citations breakdown →

18.

Stasi, Roberto, Elisa Stipa, Giovanni Del Poeta, et al.. (2006). Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Lara D. Veeken. 45(11). 1432–1436. 163 indexed citations

19.

Sahota, Surinder S., Francesco Forconi, Christian H. Ottensmeier, et al.. (2002). Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood. 100(4). 1505–1507. 71 indexed citations

20.

Frewin, Rebecca, Adrianna Henson, & Drew Provan. (1997). ABC of Clinical haematology: Iron deficiency anaemia. BMJ. 314(7077). 360–360. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact